Table 3.
Therapies in the treatment of type 2 diabetes mellitus in the diabetes registry of Tyrol by age groups
| Class | 18–39 years, n (%) | 40–59 years, n (%) | 60–79 years, n (%) | 80–99 years, n (%) |
|---|---|---|---|---|
| Oral | 123 (59.4) | 1592 (71.4) | 2878 (65.1) | 425 (46.4) |
| Metformin | 114 (55.1) | 1349 (60.5) | 2077 (47.0) | 182 (19.9) |
| Gliptins | 40 (19.3) | 653 (29.3) | 1238 (28.0) | 183 (20.0) |
| Metformin or gliptins | 119 (57.5) | 1467 (65.8) | 2505 (56.7) | 296 (32.3) |
| Glitazones | 7 (3.4) | 113 (5.1) | 156 (3.5) | 13 (1.4) |
| Glucosidase inhibitors | – | 13 (0.6) | 14 (0.3) | 6 (0.7) |
| SGLT-2 inhibitors | 12 (5.8) | 128 (5.7) | 150 (3.4) | 1 (0.1) |
| Sulfonylurea analogues | 14 (6.8) | 237 (10.6) | 627 (14.2) | 168 (18.4) |
| GLP-1 analogues | 1 (0.5) | 37 (1.7) | 43 (1.0) | 2 (0.2) |
| Insulin | 27 (13.0) | 304 (13.6) | 786 (17.8) | 218 (23.8) |
| Insulin analogues | 44 (21.3) | 613 (27.5) | 1552 (35.1) | 360 (39.3) |
| Insulin or insulin analogues | 52 (25.1) | 754 (33.8) | 1908 (43.2) | 479 (52.3) |
| Bariatric surgery | 7 (3.4) | 15 (0.7) | 10 (0.2) | – |
| Life style intervention only | 54 (26.1) | 342 (15.3) | 643 (14.6) | 151 (16.5) |
| Total | 207 (100.0) | 2229 (100.0) | 4418 (100.0) | 915 (100.0) |
SGLT‑2 sodium-glucose cotransporter 2, GLP‑1 glucagon like peptide‑1